MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 21, 2007; DOI: 10.1124/mol.107.037648


0026-895X/07/7203-780-787$20.00
Mol Pharmacol 72:780-787, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.037648v1
72/3/780    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grasshoff, C.
Right arrow Articles by Antkowiak, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grasshoff, C.
Right arrow Articles by Antkowiak, B.

Modulation of Presynaptic beta3-Containing GABAA Receptors Limits the Immobilizing Actions of GABAergic Anesthetics

Christian Grasshoff, Rachel Jurd, Uwe Rudolph, and Bernd Antkowiak

Experimental Anesthesiology Section, Department of Anesthesiology, Eberhard-Karls-University, Tuebingen, Germany (C.G., B.A.); RJ Ernest Gallo Clinic and Research Center, Department of Neurology, University of California, San Francisco, Emeryville, California (R.J.); Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland (U.R.); and Laboratory of Genetic Neuropharmacology, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts (U.R.)

Intravenous GABAergic anesthetics are potent hypnotics but are rather ineffective in depressing movements. Immobility is mediated, in part, by the ventral horn of the spinal cord. We hypothesized that the efficacy of these anesthetics in producing immobility is compromised by the activation of GABAA receptors located presynaptically, which modulate GABA release onto neurons in the ventral horn. Because anesthetics acting by modulation of GABAA receptor function require GABA to be present at its binding site, a decrease in GABA release would abate their efficacy in reducing neuronal excitability. Here we report that in organotypic spinal cord slices, the efficacy of the intravenous anesthetic etomidate to depress network activity of ventral horn neurons is limited to approximately 60% at concentrations greater than 1 µM that produce immobility. Depression of spinal network activity was almost abolished in spinal slices from beta3(N265M) knock-in mice. In the wild type, etomidate prolonged decay times of GABAA receptor-mediated inhibitory postsynaptic currents (IPSCs) and concomitantly reduced the frequency of action potential-dependent IPSCs. Etomidate prolonged the decay time of GABAA receptors at all tested concentrations. At concentrations greater than 1.0 µM, anesthetic-induced decrease of GABA release via modulation of presynaptic GABAA receptors and enhancement of postsynaptic GABAA receptor-function compensated for each other. The results suggest that the limited immobilizing efficacy of these agents is probably due to a presynaptic mechanism and that GABAergic agents with a specificity for post-versus presynaptic receptors would probably have much stronger immobilizing actions, pointing out novel avenues for drug development.


Received May 1, 2007; accepted June 21, 2007

Address correspondence to: Dr. Christian Grasshoff, Experimental Anesthesiology Section, Department of Anesthesiology and Intensive Care, Eberhard-Karls-University, Schaffhausenstr. 113, D-72072 Tuebingen. E-mail: christian.grasshoff{at}uni-tuebingen.de







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics